NYSE:TMO
492.21
8.65
(1.79%)
Analysis and Opinions about TMO-N
Signal
Opinion
Expert
Chart
TOP PICK
TOP PICK
June 10, 2021
Huge profits generated from Covid have been used to expand core business, which is scientific measurement equipment. Secret sauce is that you have to use their paper cups and vials, which are being disposed of all the time. Exceptionally well run, highly acquisitive. Trades at 20x, very attractive on the pullback. Great long-term secular grower. Grows earnings at 10-20% historically. Yield is 0.23%. (Analysts’ price target is $549.42)
Show full opinionHide full opinion
Huge profits generated from Covid have been used to expand core business, which is scientific measurement equipment. Secret sauce is that you have to use their paper cups and vials, which are being disposed of all the time. Exceptionally well run, highly acquisitive. Trades at 20x, very attractive on the pullback. Great long-term secular grower. Grows earnings at 10-20% historically. Yield is 0.23%. (Analysts’ price target is $549.42)
WEAK BUY
WEAK BUY
April 26, 2021
It is one of the better run US healthcare companies with a consistent revenue profile and a good return on invested capital. It is expensive but it drives a lot of free cash flow. It was a COVID beneficiary. He prefers Boston Scientific because it is cheaper.
It is one of the better run US healthcare companies with a consistent revenue profile and a good return on invested capital. It is expensive but it drives a lot of free cash flow. It was a COVID beneficiary. He prefers Boston Scientific because it is cheaper.
TOP PICK
TOP PICK
March 30, 2021
Stockchase Research Editor: Michael O'Reilly TMO is a $173 billion market-cap company that provides scientific instruments and consumables to companies involved in COVID-19 testing, treatment and vaccine production. Management expects another 50% increase in EPS this year, following last year's 74% boost. The company grew its cash position by over $7.5 billion company and it plans to use this to further invest in new technologies. It pays a small dividend, backed by a 5% payout ratio. We would buy this with a stop loss at $390, looking to achieve $560 --upside potential over 23%. Yield 0.20% (Analysts’ price target is $559.16)
Show full opinionHide full opinionStockchase Research Editor: Michael O'Reilly TMO is a $173 billion market-cap company that provides scientific instruments and consumables to companies involved in COVID-19 testing, treatment and vaccine production. Management expects another 50% increase in EPS this year, following last year's 74% boost. The company grew its cash position by over $7.5 billion company and it plans to use this to further invest in new technologies. It pays a small dividend, backed by a 5% payout ratio. We would buy this with a stop loss at $390, looking to achieve $560 --upside potential over 23%. Yield 0.20% (Analysts’ price target is $559.16)
BUY
BUY
March 19, 2021
A cousin of Danaher. In the life sciences but more lab oriented. Just bought a company that do PCR testing for instant Covid testing. Trades a little cheaper than Danaher. A well-managed company.
A cousin of Danaher. In the life sciences but more lab oriented. Just bought a company that do PCR testing for instant Covid testing. Trades a little cheaper than Danaher. A well-managed company.
BUY WEAKNESS
BUY WEAKNESS
March 1, 2021
It's coming back nicely, and it never comes down from its 52-week high. Some feel that with the pandemic winding down, them TMO's machine won't be making much money, but this stock isn't done. (Neither is Zoom Video.) During this pullback, pounce.
It's coming back nicely, and it never comes down from its 52-week high. Some feel that with the pandemic winding down, them TMO's machine won't be making much money, but this stock isn't done. (Neither is Zoom Video.) During this pullback, pounce.
BUY
BUY
February 23, 2021
A favourite medical device stock; their products are established in hospitals and medical labs. A big holding of his. Though it's been lagging in the last 4 months. He likes the current stock price and sees 20% upside this year in this stock. They do M&A well but they also grow organically. Maybe the market is waiting for them to do a big purchase. TMO does well year after year, and you can buy and hold this for a long time.
Show full opinionHide full opinionA favourite medical device stock; their products are established in hospitals and medical labs. A big holding of his. Though it's been lagging in the last 4 months. He likes the current stock price and sees 20% upside this year in this stock. They do M&A well but they also grow organically. Maybe the market is waiting for them to do a big purchase. TMO does well year after year, and you can buy and hold this for a long time.
BUY
BUY
February 11, 2021
TMO vs. VTRS VTRS has lower growth assets with fairly consistent cashflows. TMO is into tools and diagnostics. 75% of TMO's business is consumables. It's benefitting significantly from Covid, and this should continue. They blew away estimates, and so you pay a bit more for it.
COMMENT
COMMENT
February 10, 2021
TMO vs. WAT vs. DHR WAT not performing as well as Thermo Fisher or Danaher. Cash from operations has been flat in the last 4 years, whereas the other two have doubled, which is reflected in the stock price. Market share, operating margins, and pricing power impact the business model. Compare these when assessing competitors in an industry.
TMO vs. WAT vs. DHR WAT not performing as well as Thermo Fisher or Danaher. Cash from operations has been flat in the last 4 years, whereas the other two have doubled, which is reflected in the stock price. Market share, operating margins, and pricing power impact the business model. Compare these when assessing competitors in an industry.
TOP PICK
TOP PICK
February 10, 2021
Provides end-to-end service. Contact tracing for Covid. Can manufacture drugs. Great performer over the last 5-10 years. A main holding in all his portfolios. Yield is 0.18%. (Analysts’ price target is $557.05)
Show full opinionHide full opinionProvides end-to-end service. Contact tracing for Covid. Can manufacture drugs. Great performer over the last 5-10 years. A main holding in all his portfolios. Yield is 0.18%. (Analysts’ price target is $557.05)
BUY
BUY
February 1, 2021
Today they delivered a great quarter, but the stock rose only 1%. In November, it also delivered good results, and yet the stock had a rough two months. It's nuts. TMO is making a fortune from efforts to fight Covid. They're in the diagnostics business and supply drug companies with equipment to develop the drugs/vaccines that are working. The stock has rallied since the start of this year. Today, TMO reported 51% orgnanic growth driven by super sales and earnings, and great R&D for the future. Managers bullish guidance. Stock is rising to new highs.
Show full opinionHide full opinionToday they delivered a great quarter, but the stock rose only 1%. In November, it also delivered good results, and yet the stock had a rough two months. It's nuts. TMO is making a fortune from efforts to fight Covid. They're in the diagnostics business and supply drug companies with equipment to develop the drugs/vaccines that are working. The stock has rallied since the start of this year. Today, TMO reported 51% orgnanic growth driven by super sales and earnings, and great R&D for the future. Managers bullish guidance. Stock is rising to new highs.
BUY
BUY
November 16, 2020
PCR - https://en.wikipedia.org/wiki/Polymerase_chain_reaction A way to play the vaccine trade? Yes. This is far more than a PCR company. They are a premier medical device company run by a fine CEO.
Show full opinionHide full opinionPCR - https://en.wikipedia.org/wiki/Polymerase_chain_reaction A way to play the vaccine trade? Yes. This is far more than a PCR company. They are a premier medical device company run by a fine CEO.
PAST TOP PICK
PAST TOP PICK
September 23, 2020
(A Top Pick Aug 20/19, Up 56%) Great long-term grower. Serves many different industries. Tailwind with Covid and testing equipment. Fantastically well run. Have to close your eyes and just buy it. Could buy half now, more later. Don't have to worry about it fundamentally longer term.
Show full opinionHide full opinion(A Top Pick Aug 20/19, Up 56%) Great long-term grower. Serves many different industries. Tailwind with Covid and testing equipment. Fantastically well run. Have to close your eyes and just buy it. Could buy half now, more later. Don't have to worry about it fundamentally longer term.
TOP PICK
TOP PICK
July 24, 2020
They have gene sequencing technologies and others that run protein blots to help with vaccine development. They are in the diagnostic space as well. Revenues have increased with the pandemic as demand for the products are so high. Yield 0.22% (Analysts’ price target is $432.53)
Show full opinionHide full opinionThey have gene sequencing technologies and others that run protein blots to help with vaccine development. They are in the diagnostic space as well. Revenues have increased with the pandemic as demand for the products are so high. Yield 0.22% (Analysts’ price target is $432.53)
DON'T BUY
DON'T BUY
January 29, 2020
It's done very well, despite a hiccup in Q3 earnings. TMO is in the news because it makes lab equipment, and trades at 35x earnings. It has a steady growth rate, but they need a strong catalyst to grow at that high multiple.
Show full opinionHide full opinionIt's done very well, despite a hiccup in Q3 earnings. TMO is in the news because it makes lab equipment, and trades at 35x earnings. It has a steady growth rate, but they need a strong catalyst to grow at that high multiple.
DON'T BUY
DON'T BUY
January 17, 2020
A diversified lab equipment and diagnostics company. They also have an industrial component to their business. They are not part of their fund. The earnings multiple for the sector expanded by 20x. Basically, you are paying more for the same company. That's okay for a growth company but you have to execute perfectly. It is one of the safer choices, but he thinks it's a little too rich now.
Show full opinionHide full opinionA diversified lab equipment and diagnostics company. They also have an industrial component to their business. They are not part of their fund. The earnings multiple for the sector expanded by 20x. Basically, you are paying more for the same company. That's okay for a growth company but you have to execute perfectly. It is one of the safer choices, but he thinks it's a little too rich now.
Thermo Fisher Scientific(TMO-N) Rating
Ranking : 5 out of 5
Bullish - Buy Signals / Votes : 8
Neutral - Hold Signals / Votes : 0
Bearish - Sell Signals / Votes : 0
Total Signals / Votes : 8
Thermo Fisher Scientific(TMO-N) Frequently Asked Questions
What is Thermo Fisher Scientific stock symbol?
Thermo Fisher Scientific is a American stock, trading under the symbol TMO-N on the New York Stock Exchange (TMO). It is usually referred to as NYSE:TMO or TMO-N
Is Thermo Fisher Scientific a buy or a sell?
In the last year, 8 stock analysts published opinions about TMO-N. 8 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is TOP PICK. Read the latest stock experts' ratings for Thermo Fisher Scientific.
Is Thermo Fisher Scientific a good investment or a top pick?
Thermo Fisher Scientific was recommended as a Top Pick by John O'Connell, CFA on 2021-06-10. Read the latest stock experts ratings for Thermo Fisher Scientific.
Why is Thermo Fisher Scientific stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Thermo Fisher Scientific worth watching?
8 stock analysts on Stockchase covered Thermo Fisher Scientific In the last year. It is a trending stock that is worth watching.
What is Thermo Fisher Scientific stock price?
On 2021-06-22, Thermo Fisher Scientific (TMO-N) stock closed at a price of $492.21.
